多瑞吉对中重度晚期肝癌疼痛早期缓解效果的研究  

Study on early therapeutic efficacy of durogesic in moderate or severe pain of advanced liver cancer

作　　者：王蓉[1] 吴秀红[1] 

机构地区：[1]苏州大学附属第一医院介入科,215006

出　　处：《齐齐哈尔医学院学报》2009年第23期2876-2878,共3页Journal of Qiqihar Medical University

摘　　要：目的研究多瑞吉(芬太尼透皮贴剂)对中重度晚期肝癌癌痛的早期镇痛效果及安全性。方法选择具有中重度癌痛的晚期肝癌患者40例,随机分为多瑞吉治疗组和安慰贴对照组,观察记录用药后第1天(3h,6h,9h,12h,24h)的疼痛强度、重要生命体征、生活质量评分和不良反应。结果多瑞吉治疗组中除2例患者因用药后出现严重的恶心、呕吐不能耐受而停药外,至用药后24h中度疼痛组缓解有效率为81.8%,重度疼痛组为88.9%,两组比较无显著性差异(P>0.05)。患者早期生活质量改善明显,较治疗前有显著性差异(P<0.05),安慰贴对照组治疗前后疼痛感缓解不明显(P>0.05)。多瑞吉治疗早期不良反应以恶心、呕吐、头晕为主,发生率较低,多数患者经对症处理后可缓解,未见呼吸抑制、成瘾发生。结论芬太尼透皮贴剂治疗晚期肝癌疼痛,镇痛效果显著而稳定,使用安全方便。治疗过程中应加强对早期不良反应的观察及处理,可避免严重并发症的发生,有效改善患者的生活质量。Objective To evaluate the efficacy of durogesic used for relieving pain in liver cancer patients with moderate or severe pain. Methods 40 patients of liver cancer were divided into two groups：durogesic patch used group and control group. The entire patch was set on skin of trunk or humeral. Effect of pain easement,Karnofsky score and adverse reactions were measured at 3,6,9,12,24 hours after operation. Results There were two patients departed from the research for the unbearable nausea and vomiting. The overall effective rates of patients with moderate and severe pain were 81.8% and 88.9% respectively at 24h （P〈0.05）. In the control group the effective rate was 30% with no statistics difference （P〉0.05）. And the life quality of patients was improved significantly（P〈0.05）.The incidence of adverse reaction in early stage was low,mainly include nausea,vomiting and vertigo,and most of them can be eased through therapy. No addiction and depression of respiration were observed in this group. Conclusions The therapeutic effectiveness of durogesic is stable and safe.Enhancement of the observing adverse effect in early time is helpful to avoid serious complications and to improve the life quality of patients.

关 键 词：癌性疼痛 多瑞吉 不良反应 

分 类 号：R735.7[医药卫生—肿瘤] R730.53[医药卫生—临床医学]